GIP and lipodystrophy: These data suggest that GLP-1 RAs or dual GIP/GLP-1 receptor agonists may offer metabolic improvement in some patients with lipodystrophy, including scenarios where daily injections are not tolerated or in geographical regions where metreleptin is not available.